NASDAQ$PCVX
Vaxcyte Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Vaxcyte reported a net loss despite increased investments and progress in clinical programs.
Vaxcyte reported a net loss of $137.1 million for Q4 2024, driven by higher R&D and G&A expenses. The company made significant progress in its clinical programs, including VAX-31 and VAX-24 studies, and raised $2.2 billion in net proceeds from two equity offerings during the year.
- Net loss for Q4 2024 was $137.1 million.
- R&D expenses increased to $133.6 million for Q4 2024.
- Cash, cash equivalents, and investments totaled $3.1 billion as of December 31, 2024.
- Significant progress in VAX-31 and VAX-24 clinical programs.
Headline financials
Revenue & EPS history
Vaxcyte · Revenue · Quarterly
$0
Forward guidance
Vaxcyte expects continued progress in its clinical programs, with data readouts for VAX-24 and VAX-31 in 2025 and 2026.
Tailwinds
- VAX-31 adult Phase 3 pivotal study set to begin by mid-2025.
- Topline data from VAX-24 infant Phase 2 study expected in Q1 2025.
- Continued strong cash position to support clinical programs.
- Investments in global manufacturing readiness.
- Ongoing focus on carrier-sparing platform for PCVs.
Headwinds
- Projected continued net losses.
- High R&D spending due to ongoing trials.
- Uncertainty in clinical trial results.
- Potential delays in regulatory approvals.
- No revenue generation until commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
+0.6%
Avg return
Earnings day
+0.8%
Avg return
5 days after
-0.2%
Avg return
30 days after
50%
11 / 22 earnings
Positive
+23.8%
Q2 2020
Best reaction
-21.5%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +2.7% | +1.0% | -13.3% | |
| Q3 2025 | -2.5% | +3.8% | +12.4% | |
| Q2 2025 | -9.1% | -9.1% | +0.1% | |
| Q1 2025 | +8.3% | +3.6% | +27.6% | |
| Q4 2024 | -0.9% | -9.1% | -12.5% | |
| Q3 2024 | -2.3% | +0.2% | -15.4% | |
| Q1 2024 | -2.9% | -2.7% | +5.1% | |
| Q4 2023 | -4.9% | -9.2% | -13.5% | |
| Q3 2023 | -1.0% | -5.1% | +10.8% | |
| Q2 2023 | -2.5% | -2.0% | +3.4% | |
| Q1 2023 | +3.7% | -3.7% | -0.3% | |
| Q4 2022 | -1.8% | +2.0% | -11.6% | |
| Q3 2022 | +4.2% | +3.3% | +0.6% | |
| Q2 2022 | +0.4% | +1.7% | +6.1% | |
| Q1 2022 | -11.4% | -3.0% | -14.8% | |
| Q4 2021 | +5.5% | +1.5% | +6.5% | |
| Q3 2021 | +3.4% | +4.7% | -12.7% | |
| Q2 2021 | +5.1% | +3.6% | +3.1% | |
| Q1 2021 | +13.5% | +17.0% | +40.5% | |
| Q4 2020 | -21.5% | -11.9% | -17.3% | |
| Q3 2020 | +3.9% | -0.2% | -15.3% | |
| Q2 2020 | +23.8% | +31.0% | +5.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro